5 research outputs found
Additional file 1: of Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease
Supplemental analyses. Table S1. Clinical characteristics of patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S2. Results of the six-minute walk test for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S3. Spearman’s correlations among six-minute walk test parameters and clinical parameters for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S4. Spearman’s correlations among six-minute walk test parameters and 36-Item Short Form Health Survey and St George’s Respiratory Questionnaire scores for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S5. Multivariate analysis for predictors of 36-Item Short Form Health Survey and St George’s Respiratory Questionnaire scores for patients with pulmonary Mycobacterium avium complex disease in the never smoker group (n = 92). Table S6. Comparisons of six-minute walk test parameters and 36-Item Short Form Health Survey and St George’s Respiratory Questionnaire scores with or without cavitary lesions (n = 103). Table S7. Comparisons of clinical characteristics in pulmonary Mycobacterium avium complex disease patients between male and female (n = 103). Table S8. Multivariate analysis for predictors of 36-Item Short Form Health Survey and St George’s Respiratory Questionnaire scores for patients with pulmonary Mycobacterium avium complex disease in female alone (n = 80). Table S9. Comparisons of 36-Item Short Form Health Survey and St George’s Respiratory Questionnaire scores with or without several clinical parameters (n = 103). (DOCX 55 kb
Exotic hadrons bend the rules
The equipment used to measure the aerosolized particle sizes (Mastersizer 2000: Malvern Instruments Ltd., Worcestershire, UK). (DOCX 251 kb
Additional file 1: Table S1. of The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
Five different conditions were tried for the nebulization of amikacin sulphate. (DOCX 24 kb
Additional file 2: Table S2. of The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
Nebulizing time and speed, final remaining dose and the particle size in the compressor nebulizer. A digital weighing scale was used to measure the mean nebulizing speed and the final remaining dose. The particle sizes were measured using a Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, UK). (DOCX 186 kb
Additional file 5: Figure S2. of The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
Particle sizes and solution volumes in condition 1, condition 2 and condition 5. The aerosolized particle sizes were measured using a Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, UK). (DOCX 243 kb